Skip to main content
NCBI home page
Journal of Clinical and Experimental Hepatology logoLink to Journal of Clinical and Experimental Hepatology
editorial
. 2012 Apr 12;2(1):3–6. doi: 10.1016/S0973-6883(12)60076-0

Back from the Future: Treating Hepatitis C Virus with Conventional Interferon

Pankaj Puri *,*, Vivek A Saraswat **
PMCID: PMC3940488  PMID: 25755399

Full Text

The Full Text of this article is available as a PDF (125.7 KB).

References

  • 1.McHutchison JG, Gordon SC, Schiff ER. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485–1492. doi: 10.1056/NEJM199811193392101. [DOI] [PubMed] [Google Scholar]
  • 2.Poynard T, Marcellin P, Lee SS. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 1998;352:1426–1432. doi: 10.1016/s0140-6736(98)07124-4. [DOI] [PubMed] [Google Scholar]
  • 3.Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when east meets west. J Gastroenterol Hepatol. 2009;24:336–345. doi: 10.1111/j.1440-1746.2009.05789.x. [DOI] [PubMed] [Google Scholar]
  • 4.Hofmann WP, Zeuzem S. A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol. 2011;8:257–264. doi: 10.1038/nrgastro.2011.49. [DOI] [PubMed] [Google Scholar]
  • 5.Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433–1444. doi: 10.1002/hep.24641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Puri P. Interleukin 28B polymorphisms and hepatitis C-translating the association into clinical decision making. J Clin Exp Hepatol. 2011;1:27–33. doi: 10.1016/S0973-6883(11)60115-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Sievert W, Altraif I, Razavi HA. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011;31(Suppl 2):61–80. doi: 10.1111/j.1478-3231.2011.02540.x. [DOI] [PubMed] [Google Scholar]
  • 8.Acharya SK, Sreenivas V, Gupta SD. Treatment of chronic hepatitis due to hepatitis C virus (CH-C) in India: a randomized control trial comparing daily interferon alpha-2b and ribavirin with daily interferon alpha-2b and glycyrrhizin-a multicentre study. J Clin Exp Hepatol. 2012;2:10–18. doi: 10.1016/S0973-6883(12)60079-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Orlent H, Hansen BE, Willems M. Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial. J Hepatol. 2006;45:539–546. doi: 10.1016/j.jhep.2006.05.015. [DOI] [PubMed] [Google Scholar]
  • 10.Stickel F, Schuppan D. Herbal medicine in the treatment of liver disease. Digest Liver Dis. 2007;39:293–304. doi: 10.1016/j.dld.2006.11.004. [DOI] [PubMed] [Google Scholar]
  • 11.Tohra SK, Taneja S, Ghosh Sharma BK. Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C. Dig Dis Sci. 2011;56:2449–2455. doi: 10.1007/s10620-011-1770-3. [DOI] [PubMed] [Google Scholar]
  • 12.Manns MP, McHutchison JG, Gordon SC, et al. Reduced dose and duration of pegylated interferon alpha 2b and weight based ribavirin in Europian and Asian genotype 2 and 3 chronic hepatitis C patients (REDD2/REDD3 trial). Presented in 44th annual EASL conference, Copenhagen, 26th April 2009.
  • 13.Bochud PY, Cai T, Overbeck K. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol. 2009;51:655–666. doi: 10.1016/j.jhep.2009.05.016. [DOI] [PubMed] [Google Scholar]
  • 14.Nkontchou G, Ziol M, Aout M. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat. 2011;18:e516–e522. doi: 10.1111/j.1365-2893.2011.01441.x. [DOI] [PubMed] [Google Scholar]
  • 15.Foster GR, Hezode C, Bronowicki JP. Telepravir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology. 2011;141:881–889. doi: 10.1053/j.gastro.2011.05.046. [DOI] [PubMed] [Google Scholar]
  • 16.Scherzer TM, Hofer H, Staettermayer AF. Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. J Hepatol. 2011;54:866–871. doi: 10.1016/j.jhep.2010.08.024. [DOI] [PubMed] [Google Scholar]
  • 17.Puoti M, Minola E, Antonini MG. HCV genotype 2 and 3 respond differently to anti HCV therapy. J Hepatol. 2008;48(Suppl 2):S308. [Google Scholar]
  • 18.Andriulli A, Leandro G, Mangia A, Lacobellis A, Ippolito A, Zeuzem S. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther. 2008;28:397–404. doi: 10.1111/j.1365-2036.2008.03763.x. [DOI] [PubMed] [Google Scholar]
  • 19.Duarte-Rojo A, Heathcote EJ, Feld JJ. ‘Easy to treat’ genotypes were not created equal: can rapid virological response (RVR) level the playing field? J Hepatol. 2011;55:466–473. doi: 10.1016/j.jhep.2011.02.004. [DOI] [PubMed] [Google Scholar]
  • 20.Sarin SK, Kumar CNK. Treatment of patients with genotype 3 chronic hepatitis C-current and future therapies. Liver Int. 2012;32(Suppl 1):141–145. doi: 10.1111/j.1478-3231.2011.02715.x. [DOI] [PubMed] [Google Scholar]
  • 21.Lawson A. A comparison of the natural history and outcome of treatment for Asian and non-Asian hepatitis C-infected patients. J Viral Hepatitis. 2011;18:e270–e277. doi: 10.1111/j.1365-2893.2010.01406.x. [DOI] [PubMed] [Google Scholar]
  • 22.Freshwater DA, O'Donnell, Mutimer DJ. Inferior response of Asian vs. non-Asian hepatitis C genotype 3 infection to combination antiviral therapy. J Viral Hepatitis. 2008;15:115–119. doi: 10.1111/j.1365-2893.2007.00899.x. [DOI] [PubMed] [Google Scholar]
  • 23.Sood A, Midha V, Hissar S. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience. J Gastroenterol Hepatol. 2008;23:203–207. doi: 10.1111/j.1440-1746.2007.05057.x. [DOI] [PubMed] [Google Scholar]
  • 24.David J, Rajasekar A, Daniel HDD. Infection with hepatitis C virus genotype 3-experience of a tertiary health care center in south India. Indian J Med Microbiol. 2010;28:155–157. doi: 10.4103/0255-0857.62495. [DOI] [PubMed] [Google Scholar]
  • 25.Sood A, Midha V, Sood N, Bansal M. Pegylated interferon alfa 2b and oral ribavirin in patients with HCV-related cirrhosis. Indian J Gastroenterol. 2006;25:283–285. [PubMed] [Google Scholar]
  • 26.Ghany MG, Strader DB, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–1374. doi: 10.1002/hep.22759. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Aghemo A, Rumi MG, Soffredini R. Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection. Antivir Ther. 2006;11:797–802. [PubMed] [Google Scholar]
  • 28.Mangia A, Bandiera F, Montalto G. Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3. J Hepatol. 2010;53:1000–1005. doi: 10.1016/j.jhep.2010.04.042. [DOI] [PubMed] [Google Scholar]
  • 29.Reiser M, Buggisch P, Grossmann J, Koop K, Wursthorn K, Schmiegel W. First-line therapy with daily versus thrice-weekly interferon alfa-2b plus ribavirin for chronic hepatitis C. Eur J Gastroenterol Hepatol. 2003;15:1299–1304. doi: 10.1097/00042737-200312000-00008. [DOI] [PubMed] [Google Scholar]
  • 30.Poynard T, Leroy V, Cohard M. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology. 1996;24:778–789. doi: 10.1002/hep.510240405. [DOI] [PubMed] [Google Scholar]
  • 31.Hazari S, Panda SK, Gupta SD, Batra Y, Singh R, Acharya SK. Treatment of hepatitis C virus infection in patients of northern India. J Gastroenterol Hepatol. 2004;19:1058–1065. doi: 10.1111/j.1440-1746.2004.03405.x. [DOI] [PubMed] [Google Scholar]
  • 32.Sulkowski MS, Felizarta F, Smith C. Daily versus thrice weekly interferon alfa 2-b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial. J Acquir Immune Defic Syndr. 2004;35:464–472. doi: 10.1097/00126334-200404150-00004. [DOI] [PubMed] [Google Scholar]
  • 33.Horsmans Y, Colle I, Van Vlierberghe H. Weekly pegylated interferon alpha-2b vs. daily interferon a-2b versus standard regimen of interferon a-2b in the treatment of patients with chronic hepatitis C virus infection. Acta Gastroenterol Belg. 2008;71:293–297. [PubMed] [Google Scholar]

Articles from Journal of Clinical and Experimental Hepatology are provided here courtesy of Elsevier

RESOURCES